Ultralife: Revenue Missed, But Margin Inflection And Record Backlog Justify The Rally

Upgrade to Buy. The question is not whether Ultralife's Q2 2026 quarter was a headline miss — it was, on both revenue and EPS. The question is whether the market's 19% rally has any operating basis, or whether it is just another small-cap name chasing narrative. In this case, the rally has substance. Ultralife is a company that is expanding margins and filling its backlog while Wall Street is still pricing it as if revenue is the only metric that matters.

What Happened

Ultralife (NASDAQ: ULBI) reported Q2 2026 revenue of $47.9 million, down 1.4% from a year ago and well below the $55 million consensus estimate. GAAP EPS came in at $0.15 versus a $0.19 forecast. By headline numbers, the quarter was a miss on both lines.

But the stock jumped 19.4%, from $5.32 to $6.35, because the underlying quarter told a different story. Operating profit more than doubled year-over-year, rising 47.8% to $3.4 million. Net income rose from $0.9 million to $2.5 million. Adjusted EBITDA — a rough proxy for cash earnings before the noise of interest, taxes, and depreciation — reached $6.1 million, or 12.8% of revenue, up sharply from $4.1 million (8.5%) in the year-ago quarter.

The real driver was margin. Consolidated gross margin expanded 500 basis points to 28.9%, up from 23.9%. Roughly 230 basis points of that expansion came from a $1.1 million refund of previously paid IEEPA tariffs — a one-time credit. Strip that out, and the adjusted gross margin was still 25.8%, a 190-basis-point organic improvement. That margin expansion on flat revenue is what turned a mediocre top line into a much better bottom line.

The Backlog Signal

The most important number in the quarter may not be on the income statement at all. Ultralife's backlog — orders received but not yet shipped, a forward view of future revenue — reached a record $117.5 million at quarter end, up 39% from $84.5 million a year ago. Management said July order activity pushed the backlog toward $130 million.

Why that matters: for a small-cap defense and specialty power supplier, backlog is the leading indicator. A 39% year-over-year increase means future quarters have visibility that this quarter's revenue did not show. More than $14 million of the backlog comes from products released in the past year — conformal wearable batteries, NATO manpack radio batteries, and new amplifiers. That is not old business rolling over. That is new product adoption.

The replenishment rate — the share of orders that represent repurchasing customers rather than first-time buys — sits at 63% of trailing twelve-month sales. That is a health metric for a company in this business. It means the existing customer base is not leaking orders.

The Segment Breakdown

The Battery & Energy Products segment, which accounts for the bulk of Ultralife's revenue, came in at $44.2 million, down 3.7% year-over-year. Government defense sales fell 1.4%, and management attributed the softness to a large allied-country order that shipped in the comparable prior-year quarter — a timing headwind, not a demand problem. Commercial sales declined, weighed down by lower oil-and-gas volumes. Medical battery sales were a bright spot, up 7.2%.

Battery segment gross margin improved to 28.3% from 23.6%, a 470-basis-point jump. Excluding the tariff refund, that was still 25.8%, up 220 basis points organically.

Communications Systems, the smaller but higher-growth division, surged 39.3% to $3.8 million from $2.7 million, with gross margin expanding to 36.3% from 28.4%. This segment is the one management is betting on for the next growth phase — it supplies ruggedized communications equipment, edge-compute platforms, and power systems for military and special operations use.

Margin Improvement: One-Time Versus Structural

The $600,000–$800,000 in annual gross-margin savings from two manufacturing initiatives at the Raynham facility is the structural part of the margin story. One initiative resolved a major scrap issue on the largest margin-impacting product line, with benefits already visible in late Q2. The other corrected a supply-chain inefficiency on the second-largest margin drag, with benefits expected in mid-Q3. These are not aspirational targets. They are engineering fixes that management has already implemented.

The $1.1 million tariff refund, by contrast, is a one-time credit. The Q2 operating expense total of $10.4 million also included $0.9 million in one-time costs for cyber-insurance litigation and manufacturing consulting. Net the one-time items out and the underlying margin improvement was still substantial, but the headline 500-basis-point expansion does not repeat verbatim in Q3.

Management also raised new-product development costs by 39.1%, reflecting investment in the Communications Systems pipeline and thin-cell battery technology. That spending is a near-term drag on operating margins but is directed at programs that management expects to convert to revenue starting in 2027.

Valuation

At a $106 million market cap and 0.56 times trailing sales, Ultralife is priced as if the business is a slow-growth commodity manufacturer. The forward P/E of roughly 19x looks elevated in isolation, but it applies to earnings that just doubled and are running on an expanding margin base. EV/sales sits at 0.77x, and the PEG ratio — forward P/E divided by the earnings growth rate — is at 0.05, which suggests the multiple has not kept pace with the earnings inflection the quarter just showed.

The balance sheet is workable but not pristine. Total debt of $90.9 million against a $106 million market cap means the capital structure is debt-heavy for a company this size. Cash of $8.9 million and working capital of $69.8 million give the company a current ratio of 2.9, which is comfortable. Net debt of $38.7 million is manageable but not trivial. Free cash flow over the trailing twelve months fell 85% to $2.0 million, which is a caution flag — the company is generating less cash now than it was a year ago, even as profitability improved on an accrual basis.

What's Missing

Ultralife did not provide explicit full-year 2026 revenue or earnings guidance. That is a data gap worth flagging. The company is clearly expecting backlog to flow through into revenue, and management described itself as "well-positioned for revenue growth." But without a specific revenue or earnings range, the forward case rests on the backlog number, the margin trajectory, and the Communications Systems pipeline rather than a committed target.

Risks

• Revenue has not reaccelerated. The backlog is record, but Q2 revenue was still down 1.4% year-over-year. Backlog-to-revenue conversion can be disrupted by supply constraints, customer timing shifts, or program delays.
• Free cash flow collapsed. The 85% year-over-year decline in FCF is the most worrisome metric on the page. Improving profitability on an accrual basis means little if cash does not follow. Inventory of $54 million is high relative to quarterly revenue, which could be tying up cash in work-in-progress or finished goods.
• One-time items inflated Q2 margins. The $1.1 million tariff refund and $0.9 million in one-time operating costs mean the organic margin picture was better but not as spectacular as the headline. Q3 will show whether the manufacturing fixes alone sustain the improvement.
• Debt load. $90.9 million in total debt for a $106 million company means there is limited room for a prolonged earnings miss or interest-rate sensitivity.

Catalyst Clock

The next two quarters carry the proof burden. The manufacturing margin savings are expected to show through starting in mid-Q3, giving the third quarter a better margin base than Q2's organic level. July backlog approaching $130 million suggests H2 2026 revenue should be above the Q1–Q2 run rate, assuming normal conversion. The Communications Systems division is targeting programs — defense drones, surveillance power packs, and edge-compute platforms — for production beginning in early 2027, which means 2027 is the year the second growth curve needs to show revenue, not just pipeline.

Bottom Line

Ultralife missed the consensus estimates for Q2 revenue and EPS. But the company that just doubled operating profit, pushed backlog to a record, and identified concrete margin fixes is not the same company Wall Street priced before the quarter. The valuation at 0.77x EV/sales and a forward P/E of 19x is not cheap on brand name — it is cheap on the margin trajectory and backlog visibility. If H2 2026 revenue flows through the $130 million backlog and the manufacturing improvements hold, the earnings estimate of roughly $0.82 for the full year is a floor, not a ceiling.

Rating: Buy. The risk/reward has shifted in Ultralife's favor. The stock is trading like a slow-growth manufacturer when the evidence points to a margin-expanding business with a record order book. The data gap on guidance and the free cash flow decline keep this from being a high-conviction position, but at these levels, the valuation has already absorbed more bad news than the business is delivering.

What would change my view: A Q3 quarter where backlog fails to convert into revenue growth, or where the manufacturing margin fixes do not materialize. That would signal that Q2 was a one-time inflection rather than a structural improvement. Conversely, a Q3 that shows both revenue acceleration and sustained margin above the prior-year level would confirm the earnings power is real and the market is still underestimating it.